Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 4, 2013, Pages 412-416

  Morrow, Brian J ^a   Pillar, Christopher M ^b   Deane, Jennifer ^b   Sahm, Daniel F ^b   Lynch, A Simon ^a   Flamm, Robert K ^a   Peterson, Janet ^a   Davies, Todd A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Carbapenem; Pseudomonas aeruginosa; Surveillance; Susceptibility

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTAZIDIME; COLISTIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PUERTO RICO; UNITED STATES; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PUERTO RICO; UNITED STATES; YOUNG ADULT;

EID: 84875271162     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.12.012     Document Type: Article

References (15)

1. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
2. Breidenstein E.B., de la Fuente-Núñez C., Hancock R.E. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011, 19:419-426.
3. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-ninth edition: approved standard M07-A9 2012, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement M100-S22 2012, CLSI, Wayne, PA.
5. Davies T.A., Queenan A.M., Morrow B.J., Shang W., Amsler K., He W., et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011, 66:2298-2307.
6. Eagye K.J., Kuti J.L., Sutherland C.A., Christensen H., Nicolau D.P. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther 2009, 31:2678-2688.
7. Flamm R.K., Weaver M.K., Thornsberry C., Jones M.E., Karlowsky J.A., Sahm D.F. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004, 48:2431-2436.
8. Friedland I., Gallagher G., King T., Woods G.L. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. J Chemother 2004, 16:437-441.
9. Gaynes R., Edwards J.R., System N.N.I.S. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005, 41:848-854.
10. Jones R.N. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010, 51:S81-S87.
11. Kallen A.J., Hidron A.I., Patel J., Srinivasan A. Multidrug resistance among Gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010, 31:528-531.
12. Lister P.D., Wolter D.J., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009, 22:582-610.
13. Obritsch M.D., Fish D.N., MacLaren R., Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004, 48:4606-4610.
14. Rhomberg P.R., Jones R.N. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009, 65:414-426.
15. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008, 197:1079-1081.